Frost Radar : 제약 및 생명공학용 실험실 정보 관리 시스템(LIMS) 시장(2025년)
Frost Radar: Pharmaceutical and Biotech Laboratory Information Management Systems, 2025
상품코드:1857181
리서치사:Frost & Sullivan
발행일:2025년 09월
페이지 정보:영문 20 Pages
라이선스 & 가격 (부가세 별도)
한글목차
주요 기업을 자극하는 벤치마킹 시스템 - 새로운 이슈의 흐름과 성장 파이프라인을 촉진하는 혁신
실험실 정보 관리 시스템(LIMS) 시장은 실험실이 운영 현대화, 규정 준수 개선, 의사 결정 가속화를 추구함에 따라 급속한 변화를 겪고 있습니다. 실험실 워크플로우의 디지털화와 이질적인 데이터 소스 통합에 대한 압박은 LIMS를 가치 사슬 전반에 걸친 효율성과 혁신의 핵심 촉진제로 자리매김하고 있습니다. 이러한 변화의 주요 촉진요인은 클라우드 기반 및 서비스 주도 모델로의 전환입니다. 구현, 검증, 지속적인 유지보수 등의 서비스는 이미 업계 수익의 상당 부분을 차지하고 있으며, SaaS 및 하이브리드 전개 옵션은 기존 온프레미스 시스템 대비 유연성과 비용 효율성으로 인해 점점 더 인기를 얻고 있습니다.
제약 및 생명공학 업계는 엄격한 규제 환경과 데이터 추적성, 공정 표준화, 수동 오류를 줄이는 자동화된 실험실 워크플로우에 대한 필요성으로 인해 여전히 매출의 약 50%를 차지하는 주요 시장 부문입니다. Frost & Sullivan은 제약 및 생명공학 워크플로우를 지원하는 상위 13개 공급업체를 이 Frost Radar(TM)에 독자적으로 표시했습니다.
Frost & Sullivan은 업계의 수많은 기업을 분석합니다. 그 중에서도 리더십과 그 밖의 우수성을 바탕으로 한층 더 분석하기 위해 선정된 기업을 10항목의 '성장'과 '이노베이션' 기준으로 벤치마크하여 Frost Radar(TM)에서의 위치를 밝힙니다. Frost Radar(TM)에 게재된 각 기업의 경쟁 프로파일을 보여주며, 각 기업의 강점과 그 강점에 가장 적합한 비즈니스 기회를 고찰합니다.
전략적 과제와 성장 환경
모범 사례와 성장 기회
목차
전략적 과제와 성장 환경
Frost Radar : 제약 및 생명공학용 LIMS
Frost Radar : 주요 기업
Agaram Technologies
AmpleLogic
Benchling
BIOVIA
Caliber
L7 Informatics
LabVantage Solutions
LabWare
Sapio Sciences
Siemens Digital Industries
STARLIMS
Thermo Fisher Scientific
Xybion
모범 사례와 성장 기회
Frost Radar 분석
Frost Radar : 미래의 성장 가능성을 벤치마킹, 2개의 주요 지표, 10개의 분석 성분, 1개의 플랫폼
다음 단계 : Frost Radar를 활용하여 주요 이해관계자의 역량을 강화합니다.
Frost Radar에 게재되는 의미
Frost Radar는 CEO의 성장팀 역량을 강화합니다.
Frost Radar는 투자자 역량을 강화합니다.
Frost Radar는 고객 역량을 강화합니다.
Frost Radar는 이사회 역량을 강화합니다.
다음 단계
면책사항
HBR
영문 목차
영문목차
A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines
The laboratory information management systems (LIMS) market is undergoing a rapid transformation as laboratories look to modernize operations, improve compliance, and accelerate decision-making. The pressure to digitize lab workflows and integrate disparate data sources is positioning LIMS as a central enabler of efficiency and innovation across the value chain. A significant driver of this transformation is the shift toward cloud-based and service-led models. Services such as implementation, validation, and ongoing maintenance already account for a large share of industry revenue, while SaaS and hybrid deployment options are becoming more popular because of their flexibility and cost-effectiveness compared to traditional on-premises systems.
The pharmaceutical and biotechnology industries remain the dominant market segments, contributing close to 50% of revenue, because of the strict regulatory environment and the need for data traceability, process harmonization, and automated laboratory workflows that reduce manual errors. Frost & Sullivan independently plotted the top 13 providers supporting pharma and biotech workflows on this Frost Radar™.
Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar™. The publication presents competitive profiles of each company on the Frost Radar™ considering their strengths and the opportunities that best fit those strengths.
Strategic Imperative and Growth Environment
Strategic Imperative
The ongoing transformation of the pharmaceutical and biotechnology sectors is driving unprecedented demand for laboratory information management systems (LIMS) capable of managing increasingly complex research and development (R&D), quality assurance/quality control (QA/QC), and manufacturing environments. Laboratories are generating more data than ever, while regulatory and operational pressures require platforms that can ensure traceability, compliance, and efficiency at scale. For vendors, this creates opportunities to deliver next-generation informatics that go beyond traditional data management and actively enable faster, smarter decision-making.
The industry is being reshaped by breakthrough technologies that are no longer optional but foundational. Artificial intelligence (AI), machine learning (ML), internet of things (IoT)-enabled instruments, and advanced analytics are now embedded in leading LIMS platforms to support predictive insights, reduce errors, and accelerate turnaround times. The rise of cloud-native deployments and modular software-as-a-service (SaaS) offerings further extends accessibility, allowing organizations of all sizes to implement solutions that are flexible, scalable, and cost-effective.
Another priority is strengthening integration across the lab ecosystem. Modern LIMS must harmonize processes across distributed sites; interconnect seamlessly with electronic laboratory notebooks (ELN), scientific data management systems (SDMS), and chromatography data systems (CDS); and provide intuitive interfaces that minimize training and maximize adoption. Vendors are differentiating themselves by offering portfolios that support end-to-end workflows, from discovery to regulated manufacturing, while embedding cybersecurity and compliance features that meet evolving regulatory expectations.
A key industry trend is the shift toward unified platforms that bring LIMS together with complementary informatics systems in a single, cohesive environment. Rather than relying on fragmented tools or costly, custom-built solutions, organizations are favoring architectures that enable seamless interoperability across the R&D and manufacturing value chain.
Growth Environment
New entrants continue to intensify competition, particularly in serving mid-tier pharma, contract research organizations (CROs), and academic laboratories. Low barriers to entry, combined with demand for configurable SaaS platforms, encourage the rise of flexible, cost-effective offerings. To stay ahead, leading companies must differentiate not only on functionality but also on services, providing validation, integration, and regulatory support that address the industry's most pressing needs.
Beyond pharma and biotech, the application of LIMS is steadily expanding into adjacent industries, such as food and beverage, energy, and cosmetics, further intensifying competition and broadening the growth environment. This cross-industry expansion underscores the strategic imperative for vendors to deliver scalable, interoperable, and value-added solutions that support diverse workflows and customer needs.
Best Practices & Growth Opportunities
Enterprise-grade LIMS solutions now focus on creating a connected digital environment that spans the full laboratory and manufacturing ecosystem. Best-in-class providers integrate seamlessly with ELN, SDMS, CDS, ERP, and MES platforms, using standardized APIs and modular architectures to guarantee interoperability. By combining LIMS with advanced analytics and visualization tools, companies deliver actionable insights that accelerate R&D, streamline QA/QC, and ensure regulatory compliance.
With cloud-based deployments becoming the default in pharma and biotech, leading vendors are going beyond basic SaaS by embedding AI, ML, and GenAI modules directly into their platforms. This approach addresses customer concerns about data security and compliance while enabling predictive quality control, anomaly detection, and real-time monitoring. The SaaS delivery model ensures faster rollout of AI-driven features, reduces infrastructure costs, and provides scalability for large enterprises and midsize labs.
Market leaders emphasize flexibility and usability. Configurable modules, adaptive dashboards, and no-code customization allow laboratories to tailor solutions to unique workflows, from discovery research to GMP manufacturing. User-friendly, intuitive interfaces reduce training time, while customizable reporting and workflow automation features enhance productivity and efficiency. By making personalization straightforward and accessible, providers are ensuring broader adoption.
Growth Opportunities
LIMS that can integrate with bioinformatics platforms, AI tools, and predictive analytics are gaining traction in genomic data management, treatment stratification, and real-time decision-making in clinical trials and diagnostics. Vendors offering AI-ready, interoperable LIMS gain a competitive edge, especially in oncology and rare disease research.
Biobanks are expanding to support large-scale population genomics, longitudinal studies, and regenerative medicine. There is a growing need for LIMS with advanced sample tracking, chain-of-custody features, and compliance with standards such as ISBER and GDPR.
The shift to hybrid and decentralized trials requires LIMS that support remote sample collection, integration with eClinical systems, and real-time monitoring. LIMS vendors that enable cloud-based access, mobile integration, and compliance with GxP/21 CFR Part 11 are well positioned to grow with this trend.
Table of Contents
Strategic Imperative and Growth Environment
Frost Radar: Pharmaceutical and Biotech Laboratory Information Management Systems
